Pluri (NASDAQ:PLUR – Get Free Report) and Coya Therapeutics (NASDAQ:COYA – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, analyst recommendations, institutional ownership, dividends, valuation and profitability.
Profitability
This table compares Pluri and Coya Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pluri | -2,344.59% | N/A | -82.71% |
| Coya Therapeutics | -270.22% | -52.05% | -46.34% |
Earnings and Valuation
This table compares Pluri and Coya Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pluri | $1.02 million | 15.33 | -$23.82 million | ($2.45) | -0.51 |
| Coya Therapeutics | $7.95 million | 10.65 | -$21.23 million | ($1.07) | -3.37 |
Coya Therapeutics has higher revenue and earnings than Pluri. Coya Therapeutics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
16.6% of Pluri shares are held by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are held by institutional investors. 43.2% of Pluri shares are held by company insiders. Comparatively, 6.1% of Coya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of current recommendations for Pluri and Coya Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pluri | 1 | 0 | 0 | 0 | 1.00 |
| Coya Therapeutics | 1 | 0 | 6 | 0 | 2.71 |
Coya Therapeutics has a consensus price target of $15.33, indicating a potential upside of 324.75%. Given Coya Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Coya Therapeutics is more favorable than Pluri.
Volatility & Risk
Pluri has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Coya Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.
Summary
Coya Therapeutics beats Pluri on 9 of the 14 factors compared between the two stocks.
About Pluri
Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
About Coya Therapeutics
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Receive News & Ratings for Pluri Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluri and related companies with MarketBeat.com's FREE daily email newsletter.
